Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

50 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Activated MET is a molecular prognosticator and potential therapeutic target for malignant peripheral nerve sheath tumors.
Torres KE, Zhu QS, Bill K, Lopez G, Ghadimi MP, Xie X, Young ED, Liu J, Nguyen T, Bolshakov S, Belousov R, Wang S, Lahat G, Liu J, Hernandez B, Lazar AJ, Lev D. Torres KE, et al. Among authors: bolshakov s. Clin Cancer Res. 2011 Jun 15;17(12):3943-55. doi: 10.1158/1078-0432.CCR-11-0193. Epub 2011 May 3. Clin Cancer Res. 2011. PMID: 21540237 Free PMC article.
Vimentin is a novel anti-cancer therapeutic target; insights from in vitro and in vivo mice xenograft studies.
Lahat G, Zhu QS, Huang KL, Wang S, Bolshakov S, Liu J, Torres K, Langley RR, Lazar AJ, Hung MC, Lev D. Lahat G, et al. Among authors: bolshakov s. PLoS One. 2010 Apr 16;5(4):e10105. doi: 10.1371/journal.pone.0010105. PLoS One. 2010. Retraction in: PLoS One. 2019 Mar 21;14(3):e0214006. doi: 10.1371/journal.pone.0214006. PMID: 20419128 Free PMC article. Retracted.
An experimental model for the study of well-differentiated and dedifferentiated liposarcoma; deregulation of targetable tyrosine kinase receptors.
Peng T, Zhang P, Liu J, Nguyen T, Bolshakov S, Belousov R, Young ED, Wang X, Brewer K, López-Terrada DH, Oliveira AM, Lazar AJ, Lev D. Peng T, et al. Among authors: bolshakov s. Lab Invest. 2011 Mar;91(3):392-403. doi: 10.1038/labinvest.2010.185. Epub 2010 Nov 8. Lab Invest. 2011. PMID: 21060307 Free PMC article.
Pleomorphic liposarcoma: clinical observations and molecular variables.
Ghadimi MP, Liu P, Peng T, Bolshakov S, Young ED, Torres KE, Colombo C, Hoffman A, Broccoli D, Hornick JL, Lazar AJ, Pisters P, Pollock RE, Lev D. Ghadimi MP, et al. Among authors: bolshakov s. Cancer. 2011 Dec 1;117(23):5359-69. doi: 10.1002/cncr.26195. Epub 2011 May 19. Cancer. 2011. PMID: 21598240 Free PMC article.
SAR405838: A Novel and Potent Inhibitor of the MDM2:p53 Axis for the Treatment of Dedifferentiated Liposarcoma.
Bill KL, Garnett J, Meaux I, Ma X, Creighton CJ, Bolshakov S, Barriere C, Debussche L, Lazar AJ, Prudner BC, Casadei L, Braggio D, Lopez G, Zewdu A, Bid H, Lev D, Pollock RE. Bill KL, et al. Among authors: bolshakov s. Clin Cancer Res. 2016 Mar 1;22(5):1150-60. doi: 10.1158/1078-0432.CCR-15-1522. Epub 2015 Oct 16. Clin Cancer Res. 2016. PMID: 26475335 Free PMC article.
AXL is a potential therapeutic target in dedifferentiated and pleomorphic liposarcomas.
May CD, Garnett J, Ma X, Landers SM, Ingram DR, Demicco EG, Al Sannaa GA, Vu T, Han L, Zhang Y, Kivlin CM, Bolshakov S, Kalam AA, Liu J, Zhou F, Broccoli D, Wang WL, Lazar AJ, Pollock RE, Lev D, Torres KE. May CD, et al. Among authors: bolshakov s. BMC Cancer. 2015 Nov 14;15:901. doi: 10.1186/s12885-015-1916-3. BMC Cancer. 2015. PMID: 26573603 Free PMC article.
50 results